Vaccine supply shortage comes at a bad time, as African countries make headway with their outbreaks and have seen good uptake ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Good morning, it’s the third of July. This newsletter will be off tomorrow for the holiday and — surprise — all of next week.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

This summary encapsulates recent health updates including Carmat's insolvency filing, Bayer's glyphosate litigation in the U.S. Supreme Court, FDA's label revisions for ADHD stimulants, a U.S. House ...